In particular, this hypothesis is supported by the in vitro targeting experiments showing that ALM is capable of selectively binding ErbB2‘+’/ErbB3‘+’ tumour cells when present in a milieu of cells that express either elevated levels of one or normal levels of both target antigens. The gene discussed is ERBB3; the disease is neoplasm.